Quarterly sales (approved)
March 05, 2021 (Est)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Quartrly Sales for Cinvanti (FDA-approved drug)
WHAT IS THE CATALYST EVENT?
Approved Quarterly Sales
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
March 05, 2021 (Est)
2017: A retrospective chart review of hypersensitivity and infusion-site adverse events (ISAEs) associated with fosaprepitant IV in patients receiving anthracycline and cyclophosphamide (AC)–based chemotherapy. (Multinational Association of Supportive Care in Cancer (MASCC))
2017: Bioequivalence and safety of HTX-019 (surfactant-free aprepitant IV) and fosaprepitant in healthy subjects. (Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO))
2017: Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects. (Hematology/Oncology Pharmacy Association Annual Conference)
2020: Best practice approach to successful conversion of fosaprepitant to aprepitant IV in a large multisite community oncology infusion center: A retrospective analysis. Advances in Therapy. doi.org/10.1007/s12325-020-01377-z.
MECHANISM OF ACTION/ RATIONALE
Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis
Source - FDA Label (section 12.1)
Neurokinin-1 (NK-1) receptor antagonist:
~4 million people per year receiving chemotherapy
~CINV affects 70-80% of patients undergoing chemotherapy
Updated by HC
HRTX, Civanti, Heron, CINV, Chemotherapy-induced nausea and vomiting
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post